Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Accounts Payables: 2020-2024

Historic Accounts Payables for Foghorn Therapeutics (FHTX) over the last 5 years, with Dec 2024 value amounting to $8.5 million.

  • Foghorn Therapeutics' Accounts Payables fell 12.45% to $9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year decrease of 12.45%. This contributed to the annual value of $8.5 million for FY2024, which is 6.34% down from last year.
  • Latest data reveals that Foghorn Therapeutics reported Accounts Payables of $8.5 million as of FY2024, which was down 6.34% from $9.1 million recorded in FY2023.
  • In the past 5 years, Foghorn Therapeutics' Accounts Payables registered a high of $11.0 million during FY2022, and its lowest value of $8.5 million during FY2024.
  • Moreover, its 3-year median value for Accounts Payables was $9.1 million (2023), whereas its average is $9.5 million.
  • In the last 5 years, Foghorn Therapeutics' Accounts Payables climbed by 15.05% in 2022 and then dropped by 17.21% in 2023.
  • Yearly analysis of 5 years shows Foghorn Therapeutics' Accounts Payables stood at $9.2 million in 2020, then increased by 4.38% to $9.6 million in 2021, then rose by 15.05% to $11.0 million in 2022, then dropped by 17.21% to $9.1 million in 2023, then fell by 6.34% to $8.5 million in 2024.